KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBIT (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of EBIT data on record, last reported at $153.6 million in Q2 2025.

  • For Q2 2025, EBIT rose 22016.98% year-over-year to $153.6 million; the TTM value through Jun 2025 reached $336.8 million, up 786.66%, while the annual FY2024 figure was $218.1 million, 181.43% up from the prior year.
  • EBIT reached $153.6 million in Q2 2025 per SRPT's latest filing, down from $161.7 million in the prior quarter.
  • Across five years, EBIT topped out at $161.7 million in Q4 2024 and bottomed at -$211.1 million in Q2 2022.
  • Average EBIT over 5 years is -$52.5 million, with a median of -$86.9 million recorded in 2022.
  • Peak YoY movement for EBIT: plummeted 281.2% in 2022, then surged 22016.98% in 2025.
  • A 5-year view of EBIT shows it stood at -$105.8 million in 2021, then dropped by 0.96% to -$106.8 million in 2022, then soared by 123.05% to $24.6 million in 2023, then skyrocketed by 556.57% to $161.7 million in 2024, then dropped by 4.97% to $153.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were $153.6 million in Q2 2025, $161.7 million in Q4 2024, and $22.2 million in Q3 2024.